Dose and Timing Effects of Esomeprazole Administration on 24-H Intragastric pH Control
Kerstin Röhss(AstraZeneca (Sweden)), Tore Lind(Skaraborg Hospital), Péter Nagy(AstraZeneca (Sweden)), Sara Bokelund-Singh(Stanford University), Mohamed Sagar(AstraZeneca (Sweden)), Clive H. Wilder‐Smith, Doug Levine(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study
|Helicobacter|1996|575
The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
|Gastroenterology|1999|433
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Comparison of Outcomes Twelve Years After Antireflux Surgery or Omeprazole Maintenance Therapy for Reflux Esophagitis
|Clinical Gastroenterology and Hepatology|2009|150
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140